Indication*

(Oral) Heterozygous Familial Hypercholesterolaemia, Mixed Dyslipidaemia, Primary Hypercholesterilaemia, Homozygous Familial Hypercholesterolaemia, Prophylaxis of Cardiovascular events in High-Risk Patients.

Directions for Use*

(Oral) Heterozygous Familial Hypercholesterolaemia) Children: Dose is individualized according to baseline LCL-C levels, the goal of therapy, and patient response. As an adjunct to diet: 10-17 years Initially, 10 mg daily; may be adjusted according to response at intervals of at least 4 weeks. Usual range: 10-20 mg once daily. (Mixed Dyslipidaemia, Primary Hypercholesterilaemia) Adult: Dose is individualized according to baseline LDL-cholesterol (LDL-C) levels, the goal of therapy, and patient response. As an adjunct to diet: Usual initial dose: 10 mg or 20 mg once daily; patients who require >45% reduction in LDL-C may initiate at 40 mg once daily. Usual range: 10-80 mg once daily. Max: 80 mg once daily. Evaluate lipid levels within 2-4 weeks after initiation and/or upon titration, then adjust dose accordingly. ( Homozygous Familial Hypercholesterolaemia) Adult: Dose is individualized according to baseline LDL-C levels, the goal of therapy, and patient response. As an adjunct to other lipid-lowering treatments (e.g. LDL aphesis): 10-80 mg daily. (Prophylaxis of Cardiovascular events in High-Risk Patients) Adult: Dose is individual according to baseline LDL-C levels, the goal of therapy, and patients response. Primary prevention: Initially, 10 mg daily. Higher doses may be required to attain LDL-C levels according to current guidelines.

Administration*

May be taken with or without food. Avoid excessive consumption (>1 L/day) of grapefruit juice.

*written indications, directions, and administration are updated as of March 23, 2024 and may not be accurate with the actual product purchased. Please read the details in the packaging.

Share

Share

Link

Close share Copy link

View full details